Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has earned a consensus rating of “Buy” from the seven research firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $32.20.
A number of analysts have commented on the company. ValuEngine downgraded WideOpenWest from a “hold” rating to a “sell” rating in a research report on Friday, June 28th. HC Wainwright set a $31.00 price objective on Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Finally, Maxim Group reiterated a “buy” rating and issued a $60.00 price objective on shares of Otter Tail in a research report on Tuesday, May 7th.
Several institutional investors and hedge funds have recently modified their holdings of GLMD. BlackRock Inc. acquired a new position in shares of Galmed Pharmaceuticals in the 4th quarter worth approximately $33,000. Northern Trust Corp raised its holdings in shares of Galmed Pharmaceuticals by 16.3% in the 4th quarter. Northern Trust Corp now owns 12,215 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 1,715 shares in the last quarter. Delek Group Ltd. acquired a new position in shares of Galmed Pharmaceuticals in the 1st quarter worth approximately $173,000. Deutsche Bank AG acquired a new position in shares of Galmed Pharmaceuticals in the 4th quarter worth approximately $229,000. Finally, ARK Investment Management LLC raised its holdings in shares of Galmed Pharmaceuticals by 31.6% in the 1st quarter. ARK Investment Management LLC now owns 53,749 shares of the biopharmaceutical company’s stock worth $439,000 after buying an additional 12,905 shares in the last quarter. 35.59% of the stock is owned by institutional investors and hedge funds.
Shares of GLMD stock traded down $0.21 during mid-day trading on Monday, reaching $6.61. The stock had a trading volume of 22,814 shares, compared to its average volume of 92,084. The company has a 50 day moving average of $6.47. The company has a current ratio of 36.11, a quick ratio of 36.11 and a debt-to-equity ratio of 0.01. Galmed Pharmaceuticals has a one year low of $5.48 and a one year high of $15.98. The company has a market capitalization of $143.99 million, a price-to-earnings ratio of -12.24 and a beta of 2.67.
Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.02. As a group, sell-side analysts expect that Galmed Pharmaceuticals will post -1.14 earnings per share for the current year.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Recommended Story: What is intrinsic value?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.